US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy. 7 October 2024
Adaptimmune, a biotech company focused on the use of engineered T cells to treat cancer, has announced the full-time appointment of James Noble as chief executive officer. 26 March 2014
German pharma and chemical major Merck KGaA has announced the promotion of three distinguished internal managers to head the life-science-tools and consumer health divisions as well as its allergy business unit. 26 March 2014
Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has announced the appointment of Giles Platford as Head of Commercial Operations, Emerging Markets. 19 March 2014
UK-based company NeRRe Therapeutics, which is focused on the development of neurokinin (NK) receptor antagonists for a range of indications, has announced the appointment of Ian Nicholson as Chief Business Officer (CBO). 19 March 2014
Spherix Incorporated (NASDAQ: SPEX) have announced that Frank Reiner has joined the company as vice president of
licensing, where he will report to chief executive Anthony Hayes and play a key role in the company's licensing efforts. 19 March 2014
Avion Pharmaceuticals, a US-based specialty pharmaceutical company, has announced the promotion of Mike Sullivan to the position of president. 18 March 2014
Australian product development company Clinical Network Services (CNS) has launched a new UK office headed by Paul Cronin who joins as UK Director and Director, Business Development. 10 March 2014
US headquartered Moderna Therapeutics, a leader in the development of RNA (mRNA) Therapeutics has announced that Lorence Kim will join Moderna's executive leadership team as chief financial officer, effective April 21. 7 March 2014
Aquavit Pharmaceuticals, a private US-based life science company, has announced the appointment of David Goldberg as chief medical officer. 6 March 2014
French biopharmaceutical company Genticel has recruited Sophie Olivier as chief medical officer to lead the clinical development of its pipeline, in particular the ProCervix Phase II trial. 4 March 2014
Australian biotech company Novogen has announced the appointments of new board members and a strategic advisor to support its transition into a clinical-stage company with a growing US presence and an investor base in the USA and Australia. 4 March 2014
Executives are moving back to an ‘ex-directory’ world, where smaller, restricted networks are of the highest value, according to RSA, a global life sciences executive search and interim management specialist. 3 March 2014
Australian biotechnology firm Phosphagenics has appointed biotech industry veterans Lawrence Gozlan, Nathan Drona and Geert Cauwenbergh as non-executive directors, with Mr Gozlan assuming the role of Chairman of the Board on an interim basis. 3 March 2014
Belgium’s largest drugmaker, UCB, yesterday announced a succession plan for its chief excecutive, Roch Doliveux, saying that Jean-Christophe Tellier, currently executive vice president, Biopharma Brands and Solutions, will be appointed chief executive-elect and chairman of the executive committee as of March 1, 2014. 21 February 2014
Germany’s Merck KGaA has appointed Simon Sturge to head the biosimilars unit, effective March 1, succeeding Thierry Hulot, who created the biosimilars unit and took over responsibility for Global Manufacturing & Supply for the Merck Serono division at the end of last year. 20 February 2014